After the recent groundbreaking results from the bone marrow cancer drug Ruxolitinib (Columbia University — Dr. Angela Christiano) and the arthritis drug Tofacitinib (Dr. Brett King) on several patients with alopecia totalis, Columbia University is now expanding its testing to more volunteers and more drugs.
Here is the Columbia University Alopecia Areata Study Consent Form and Inquiry Response Form (latter at the bottom after you accept conditions). On there, they state the following —
Current study status:
Ruxolitinib — Closed to enrollment. Study procedures ongoing..
Abatacept — Currently enrolling. Total number of subjects to be enrolled: 15.
Tofacitinib — Enrollment to start approximately Sept.-Oct. Total number of subjects to be enrolled: 10-15.
Injection steroids/triamcinolone (Kenalog) — Open to enrollment.
Sites: Columbia University and the University of Minnesota.